Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 31'st May 2024
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer's drug for advanced lung cancer shows promising long-term trial results
09:00am, Friday, 31'st May 2024
Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the conditi
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
08:10am, Friday, 31'st May 2024
Pfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung can
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, avail
EU regulator recommends use of Pfizer's gene therapy for rare bleeding disorder
06:30am, Friday, 31'st May 2024
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein,
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
03:30am, Friday, 31'st May 2024
Pfizer's dividend yield is rising as the stock price is falling.
New U.S. bird-flu case is first with respiratory symptoms, CDC says
02:52pm, Thursday, 30'th May 2024
A new human bird-flu case identified in a Michigan dairy worker is the first in the U.S. to involve acute respiratory symptoms, the Centers for Disease Control and Prevention said Thursday.
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
02:45pm, Thursday, 30'th May 2024
CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Dividend Harvesting Portfolio Week 169: $16,900 Allocated, $1,503.06 In Projected Dividends
09:00am, Thursday, 30'th May 2024
Markets spooked by the Fed's language on inflation progress, causing uncertainty on rate cuts. Dividend Harvesting Portfolio retraces slightly but still generates respectable dividend income. Portfoli
Steady Gains, Solid Yields: 7 Low-Beta Stocks Paying 5%+ Dividends
06:40am, Thursday, 30'th May 2024
The stock market is not all about buying high-flying stocks that can be potential 10-baggers or 20-baggers. While growth stocks should be a part of the portfolio, it's low-beta dividend stocks that se
3 Dividend Stocks to Double Up on Right Now
05:45am, Thursday, 30'th May 2024
AbbVie is a Dividend King in good shape to deliver solid growth through the rest of the decade. Chevron should reward investors with growing dividends and the "invisible dividends" of stock buybacks.
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
02:45pm, Wednesday, 29'th May 2024
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t
7 Must-Own Stocks to Hold for the Second Half of 2024
09:31am, Wednesday, 29'th May 2024
Seven firms representing various industries stand out as prospective high-yielders as the market approaches H2 2024. Each one has distinct development drivers and value propositions.
If You Can Only Buy One Value Stock in May, It Better Be One of These 3 Names
06:00am, Wednesday, 29'th May 2024
Everyone loves discounts and that's essentially what value stocks to buy represent. The difference, though, between a value play and a “cheap” security comes down to the credibility (or lack there
Event-Driven Strategies, Commodities, And Writing Options With Asif Suria
01:00pm, Tuesday, 28'th May 2024
Asif Suria focuses on risk rather than reward with event-driven strategies. Interest in commodities, particularly copper, oil, and gold, which have been performing well.
